OncoMatch/Clinical Trials/NCT06715826
Target-specific immunoPET Imaging of Breast Cancer
Is NCT06715826 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including [18F]F-RESCA-RT4 and [18F]F-RESCA-RB14 for breast cancer.
Treatment: [18F]F-RESCA-RT4 · [18F]F-RESCA-RB14 — The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Breast Cancer Metastatic
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify